Australia medical device regulations

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.

Under Regulations 10F/10FA, qualifying sponsor succession/assignment and sponsor-name events are notified in the approved manner within three months. An agreed business/interest transfer carries the inclusion to the new sponsor when the event occurs; it is not a discretionary transfer by a foreign manufacturer. A same sponsor with unchanged ABN/ACN uses the name form; changed ABN/ACN requires new organisation identification and the applicable transfer process.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The transfer form identifies both sponsors/client IDs, affected ARTG entries, event/date and declarations by authorised representatives; extra entries use an attached list. Submit after the transfer has occurred and identify pending variations. Manufacturer Evidence is not transferred with sponsorship: the new sponsor first obtains accepted evidence, then submits DCR to link it to the ARTG. That order is separate from the legal event transferring sponsorship.

There is no fee for the sponsor transfer/name notification itself. TGA says it normally updates the ARTG within ten working days of a fully completed, signed notification and any required information; the form describes this as an aim. This administrative processing target does not defer legal sponsorship responsibility until the record is updated or price additional ARTG variations.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.

Under Regulations 10F/10FA, qualifying sponsor succession/assignment and sponsor-name events are notified in the approved manner within three months. An agreed business/interest transfer carries the inclusion to the new sponsor when the event occurs; it is not a discretionary transfer by a foreign manufacturer. A same sponsor with unchanged ABN/ACN uses the name form; changed ABN/ACN requires new organisation identification and the applicable transfer process.

One DCR may cover up to ten ARTG entries only where the requested change is the same for each entry. This is distinct from listing additional entries in a sponsor-transfer form and from the conditional 215-dollar evidence-update tariff. Separate approval prerequisites still apply; these provisions do not establish every transfer-plus-name/brand/REF event as one filing.

For Class 1-3 IVDs, adding a device of the kind that meets the notification criteria uses the IVD Variation form and the manufacturer Australian DoC. Existing ARTG information/performance or intended-purpose updates use DCR; the specified combined additional-device/intended-purpose case includes the replacement-purpose document. Do not delete an active IVD unless supply has ceased. Class 4 IVDs have a single UPI and do not use that IVD variation form. Wait for approval before implementing a variation.

The transfer form identifies both sponsors/client IDs, affected ARTG entries, event/date and declarations by authorised representatives; extra entries use an attached list. Submit after the transfer has occurred and identify pending variations. Manufacturer Evidence is not transferred with sponsorship: the new sponsor first obtains accepted evidence, then submits DCR to link it to the ARTG. That order is separate from the legal event transferring sponsorship.

There is no fee for the sponsor transfer/name notification itself. TGA says it normally updates the ARTG within ten working days of a fully completed, signed notification and any required information; the form describes this as an aim. This administrative processing target does not defer legal sponsorship responsibility until the record is updated or price additional ARTG variations.

The current-linked TGA variation guide expressly says there is no legislated timeframe for evaluating an ARTG variation. Its 3-5-business-day target applies only to the stated Class III programming-software variation after the new hardware is approved. The reasonable information-request response period of at least ten working days is an applicant deadline, not a general evaluation SLA.

For a UDI medical device, Essential Principle 13C.2 treats the listed brand-name, model/version and packaging changes as a different type of model, with corresponding database identifiers. Changes made in the same production change are treated together; the pre-change device remains its prior type. Database timing depends on the applicable general start day and supply event. A commercial REF must first be mapped to these fields; UDI consequences do not themselves determine ARTG new-kind or variation classification.

If the importing country needs a certificate, the sponsor/authorised agent may seek CFS for current Australian-supply ARTG devices or Export Certificate for export-only entries. Correct ARTG details before applying; the exports team does not amend them. The form needs sponsor/client and ARTG/GMDN details, declaration and the applicable payment; one form/one optional schedule per certificate. More than five devices need a schedule, not automatic rejection. TGA aims for ten working days; this is a separate export service, not ordinary change approval or automatic certificate reissue.

Current Schedule 9 item 2A (d) sets AUD 1982 for Class 3/4 IVD variation and (e) AUD 1133 for other IVD variation, each excluding the (g) case and data evaluation. Item (g) statutorily covers a medical device meeting all three EU-transition/sole-evidence-update/same-evidence conditions at AUD 215 per ten entries or part. The summary table describes (g) as non-IVD; preserve that discrepancy rather than impose the summary exclusion over the statute.

The shared medical-device provisions expressly cover IVDs: Essential Principle 13 requires the applicable manufacturer name/trading name, address, device identity, lot/date and English information. Regulation 10.2 also requires readily identifiable sponsor name/address; added sponsor labels must not adulterate the device or obscure manufacturer information. These are information/location requirements, not a general old-label stock grace.